Downregulation of toll-like receptor 9 expression by beta human papillomavirus 38 and implications for cell cycle control

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11396-11405

  Pacini, Laura ^a   Savini, Claudia ^a   Ghittoni, Raffaella ^a   Saidj, Djamel ^a   Lamartine, Jerome ^b   Hasan, Uzma A ^c   Accardi, Rosita ^a   Tommasino, Massimo ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ LYON 1   (France)

^c University Lyon i   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PROTEIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DELTA NP73ALPHA PROTEIN; HISTONE H3; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; MESSENGER RNA; PROTEIN E6; PROTEIN E7; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; CDK2 PROTEIN, HUMAN; CDKN1B PROTEIN, HUMAN; EZH2 PROTEIN, HUMAN; HISTONE; I KAPPA B KINASE; P21 ACTIVATED KINASE; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA; TLR9 PROTEIN, HUMAN; VIRUS RNA;

ARTICLE; BETAPAPILLOMAVIRUS; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; COMPLEX FORMATION; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 38; IMMUNE RESPONSE; INNATE IMMUNITY; KERATINOCYTE; PREPUCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL LINE; GENETICS; METABOLISM; METHYLATION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; RNA INTERFERENCE; VIROLOGY;

CELL CYCLE CHECKPOINTS; CELL LINE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; ENHANCER OF ZESTE HOMOLOG 2 PROTEIN; HISTONES; HUMANS; I-KAPPA B KINASE; KERATINOCYTES; METHYLATION; P21-ACTIVATED KINASES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA, VIRAL; TOLL-LIKE RECEPTOR 9;

EID: 84945937892     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02151-15     Document Type: Article

References (31)

1. Tommasino M. 2014. The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 26:13-21. http://dx.doi.org/10.1016/j.semcancer.2013.11.002.
2. Smola S. 2014. Human papillomaviruses and skin cancer. Adv Exp Med Biol 810:192-207.
3. Accardi R, Gheit T. 2014. Cutaneous HPV and skin cancer. Press Med http://dx.doi.org/10.1016/j.lpm.2014.08.008.
4. Bouvard V, Gabet AS, Accardi R, Sylla SB, Tommasino M. 2006. The cutaneous human papillomavirus types and non-melanoma-skin cancer, p 269-277. In Campo MS (ed), Papillomavirus research: from natural history to vaccine and beyond. Caister Academic Press, Norfolk, United Kingdom.
5. Pfister H, Fuchs PG, Majewski S, Jablonska S, Pniewska I, Malejczyk M. 2003. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent population. Arch Dermatol Res 295:273-279. http://dx.doi.org/10.1007/s00403-003-0435-2.
6. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401:70-79. http://dx.doi.org/10.1016/j.virol.2010.02.002.
7. Caldeira S, Zehbe I, Accardi R, Malanchi I, Dong W, Giarre M, de Villiers EM, Filotico R, Boukamp P, Tommasino M. 2003. The E6 and E7 proteins of the cutaneous human papillomavirus type 38 display transforming properties. J Virol 77:2195-2206. http://dx.doi.org/10.1128/JVI.77.3.2195-2206.2003.
8. Gabet AS, Accardi R, Bellopede A, Popp S, Boukamp P, Sylla BS, Londono-Vallejo JA, Tommasino M. 2008. Impairment of the telomere/telomerase system and genomic instability are associated with keratinocyte immortalization induced by the skin human papillomavirus type 38. FASEB J 22:622-632. http://dx.doi.org/10.1096/fj.07-8389com.
9. Accardi R, Dong W, Smet A, Cui R, Hautefeuille A, Gabet AS, Sylla BS, Gissmann L, Hainaut P, Tommasino M. 2006. Skin human papillomavirus type 38 alters p53 functions by accumulation of delta Np73. EMBO Rep 7:334-340. http://dx.doi.org/10.1038/sj.embor.7400615.
10. Accardi R, Scalise M, Gheit T, Hussain IS, Yue J, Carreira C, Collino A, Indiveri C, Gissmann L, Sylla BS, Tommasino M. 2011. IκB kinase β promotes cell survival by antagonizing p53 functions through δNp73α phosphorylation and stabilization. Mol Cell Biol 31:2210-2226. http://dx.doi.org/10.1128/MCB.00964-10.
11. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, Wesselborg S, Stubenrauch F, Iftner T. 2010. Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 70:6913-6924. http://dx.doi.org/10.1158/0008-5472.CAN-10-1307.
12. Viarisio D, Mueller-Decker K, Kloz U, Aengeneyndt B, Kopp-Schneider A, Grone HJ, Gheit T, Flechtenmacher C, Gissmann L, Tommasino M. 2011. E6 and E7 from beta HPV38 cooperate with ultraviolet light in the development of actinic keratosis-like lesions and squamous cell carcinoma in mice. PLoS Pathog 7:e1251002. http://dx.doi.org/10.1371/journal.ppat.1002125.
13. Saidj D, Cros MP, Hernandez-Vargas H, Guarino F, Sylla B, Tommasino M, Accardi R. 4 September 2013. The E7 oncoprotein from beta human papillomavirus type 38 induces the formation of an inhibitory complex for a subset of p53-regulated promoters. J Virol http://dx.doi.org/10.1128/JVI.01047-13.
14. Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. 2010. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol 31:391-397. http://dx.doi.org/10.1016/j.it.2010.07.004.
15. Sathish N, Yuan Y. 2011. Evasion and subversion of interferon-mediated antiviral immunity by Kaposi's sarcoma-associated herpesvirus: an overview. J Virol 85:10934-10944. http://dx.doi.org/10.1128/JVI.00687-11.
16. Hasan UA, Zannetti C, Parroche P, Goutagny N, Malfroy M, Roblot G, Carreira C, Hussain I, Muller M, Taylor-Papadimitriou J, Picard D, Sylla BS, Trinchieri G, Medzhitov R, Tommasino M. 2013. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med 210:1369-1387. http://dx.doi.org/10.1084/jem.20122394.
17. Kawai T, Akira S. 2007. Antiviral signaling through pattern recognition receptors. J Biochem 141:137-145. http://dx.doi.org/10.1093/jb/mvm032.
18. Takeda K, Akira S. 2005. Toll-like receptors in innate immunity. Int Immunol 17:1-14. http://dx.doi.org/10.1093/intimm/dxh186.
19. Fathallah I, Parroche P, Gruffat H, Zannetti C, Johansson H, Yue J, Manet E, Tommasino M, Sylla BS, Hasan UA. 2010. EBV latent membrane protein 1 is a negative regulator of TLR9. J Immunol 185:6439-6447. http://dx.doi.org/10.4049/jimmunol.0903459.
20. van Gent M, Griffin BD, BerkhoffEG, van Leeuwen D, Boer IG, Buisson M, Hartgers FC, Burmeister WP, Wiertz EJ, Ressing ME. 2011. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J Immunol 186:1694-1702. http://dx.doi.org/10.4049/jimmunol.0903120.
21. Martin HJ, Lee JM, Walls D, Hayward SD. 2007. Manipulation of the Toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 81: 9748-9758. http://dx.doi.org/10.1128/JVI.01122-07.
22. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, Tommasino M. 2007. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178: 3186-3197. http://dx.doi.org/10.4049/jimmunol.178.5.3186.
23. Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trepo C, Hasan U, Chemin I. 2011. Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells. PLoS One 6:e26315. http://dx.doi.org/10.1371/journal.pone.0026315.
24. Shahzad N, Shuda M, Gheit T, Kwun HJ, Cornet I, Saidj D, Zannetti C, Hasan U, Chang Y, Moore PS, Accardi R, Tommasino M. 2013. The T antigen locus of Merkel cell polyomavirus downregulates human Toll-like receptor 9 expression. J Virol 87:13009-13019. http://dx.doi.org/10.1128/JVI.01786-13.
25. Morgenstern JP, Land H. 1990. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 18: 3587-3596. http://dx.doi.org/10.1093/nar/18.12.3587.
26. Shatz M, Menendez D, Resnick MA. 2012. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 72:3948-3957. http://dx.doi.org/10.1158/0008-5472.CAN-11-4134.
27. Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA. 2011. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet 7:e1001360. http://dx.doi.org/10.1371/journal.pgen.1001360.
28. Tanaka Y, Ota K, Kameoka M, Itaya A, Yoshihara K. 2006. Upregulation of NFkappaB-responsive gene expression by DeltaNp73alpha in p53 null cells. Exp Cell Res 312:1254-1264. http://dx.doi.org/10.1016/j.yexcr.2005.12.013.
29. Takeshita F, Suzuki K, Sasaki S, Ishii N, Klinman DM, Ishii KJ. 2004. Transcriptional regulation of the human TLR9 gene. J Immunol 173: 2552-2561. http://dx.doi.org/10.4049/jimmunol.173.4.2552.
30. Kim GY, Mercer SE, Ewton DZ, Yan Z, Jin K, Friedman E. 2002. The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 277:29792-29802. http://dx.doi.org/10.1074/jbc. M201299200.
31. Gillet E, Meys JF, Verstraelen H, Bosire C, De SP, Temmerman M, Broeck DV. 2011. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect Dis 11:10. http://dx.doi.org/10.1186/1471-2334-11-10.